<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="systematic-review" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2024.1319845</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Medicine</subject>
<subj-group>
<subject>Systematic Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular detection of rifampicin-resistant <italic>Mycobacterium tuberculosis</italic> by polymerase chain reaction in Ethiopia: a systematic review and meta-analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Birhanu</surname> <given-names>Molla Yigzaw</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1706425/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bekele</surname> <given-names>Getamesay Molla</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2619421/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Jemberie</surname> <given-names>Selamawit Shita</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2663262/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Public Health, College of Health Sciences, Debre Markos University</institution>, <addr-line>Debre Markos</addr-line>, <country>Ethiopia</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Gynecology and Obstetrics, School of Medicine, Debre Markos University</institution>, <addr-line>Debre Markos</addr-line>, <country>Ethiopia</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Midwifery, College of Health Sciences, Debre Markos University</institution>, <addr-line>Debre Markos</addr-line>, <country>Ethiopia</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0001"><p>Edited by: Quanxin Long, Chongqing Medical University, China</p></fn>
<fn fn-type="edited-by" id="fn0002"><p>Reviewed by: Zheng Qi, Harbin University of Commerce, China</p><p>Ayo Ajayi, Federal University, Oye Ekiti, Nigeria</p></fn>
<corresp id="c001">&#x002A;Correspondence: Molla Yigzaw Birhanu, <email>molla_Yigzaw@Dmu.Edu.Et</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>11</volume>
<elocation-id>1319845</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>10</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>03</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Birhanu, Bekele and Jemberie.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Birhanu, Bekele and Jemberie</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec id="sec1">
<title>Introduction</title>
<p>Tuberculosis is a contagious bacterial disease caused by <italic>Mycobacterium tuberculosis</italic>. The emergence and spread of drug-resistant strains of <italic>M. tuberculosis</italic> in both developing and developed countries has made diagnosis, treatment, and control of tuberculosis more difficult. The PCR assay, which is a fast and sensitive technique and an alternative method for detecting multidrug-resistant tuberculosis, is used to determine rifampicin (RIF) resistance. There is no single figure in Ethiopia that represents rifampicin-resistant tuberculosis and that is why this study was conducted to overcome the inconsistency of the results of the previous studies.</p>
</sec>
<sec id="sec2">
<title>Methods</title>
<p>Studies were researched from five major electronic databases. Studies which were cross-sectional in design, published, and written in English were included. The data were extracted using Microsoft Excel, and the data were managed and analyzed using Stata&#x2122; Version 17.0 statistical software. The Forest plot was used to check the presence of heterogeneity. The publication bias, meta-regression, and subgroup analysis were used to find out the source of heterogeneity. A random effect analysis model was used to pool the prevalence of RR TB from primary studies, and associated factors of RR among TB patients were identified using Meta regression. The presence of association was reported using OR with 95% CI.</p>
</sec>
<sec id="sec3">
<title>Results</title>
<p>The overall pooled prevalence of tuberculosis was 14.9% (95% CI: 13.34, 16.46), of these approximately 7.48% (95% CI: 6.30, 8.66) showed rifampicin-resistant tuberculosis in Ethiopia. Among the computed variables, 2.05% living with HIV1.39 (95%CI: 1.13, 1.72) and having a history of TB treatment (95%CI: 1.34, 3.15) were identified as significant factors associated with RR TB in Ethiopia.</p>
</sec>
<sec id="sec4">
<title>Conclusion</title>
<p>Drug-resistant TB is one of the prevalent emerging infectious diseases among TB patients, which affects approximately one out of every thirteen TB patients. Having TB-HIV coinfection and a history of prior TB treatment were identified as significant factors associated with RR TB. To prevent and control RR TB, patients should complete their follow-up course; the health professionals should educate the actions taken by the patients when they experience drug toxicity and side effects; and the Minister of Health should initiate telemedicine and recruit tracers to overcome TB patients&#x2019; default and have good drug adherence and retention after initiation of the treatment.</p>
</sec>
</abstract>
<kwd-group>
<kwd>rifampicin-resistant</kwd>
<kwd>prevalence</kwd>
<kwd>associated factors</kwd>
<kwd>tuberculosis</kwd>
<kwd>Ethiopia</kwd>
</kwd-group>
<counts>
<fig-count count="7"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="58"/>
<page-count count="11"/>
<word-count count="6315"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Infectious Diseases: Pathogenesis and Therapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec5">
<title>Introduction</title>
<p>Tuberculosis is a communicable bacterial disease caused by <italic>Mycobacterium tuberculosis</italic> (<xref ref-type="bibr" rid="ref1">1</xref>). The bacteria primarily affect the lungs to cause pulmonary tuberculosis; however, the bacteria can affect other organs. It is one of the top ten causes of death worldwide, ranking even higher than the human immunodeficiency virus (<xref ref-type="bibr" rid="ref2">2</xref>). Nowadays, diagnosis, treatment, and control of tuberculosis are made more difficult by the emergence and increase in the spread of drug-resistant strains of <italic>M. tuberculosis</italic> found in both developing and developed countries (<xref ref-type="bibr" rid="ref3 ref4 ref5">3&#x2013;5</xref>).</p>
<p>Multidrug-resistant tuberculosis (MDR-TB) is defined as the presence of a strain of <italic>Mycobacterium tuberculosis</italic> that is resistant to at least rifampicin and/or isoniazid (<xref ref-type="bibr" rid="ref6">6</xref>). Rifampicin (RIF) is the most potent first-line anti-tuberculosis antibiotic, which is essential to the success of the current tuberculosis chemotherapy regimen. Rifampicin-resistant (RIF) necessitates treatment extension and may lead to multidrug-resistant tuberculosis in the future (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref8">8</xref>). RIF is caused by the substitution of a small number of highly conserved amino acids encoded by rpoB, the gene for the &#x03B2; subunit of <italic>Mycobacterium tuberculosis</italic> RNA polymerase (<xref ref-type="bibr" rid="ref9">9</xref>). RIF caused fewer and more expensive therapeutic options, prolonged treatment, increased toxicity, and poorer clinical outcomes (<xref ref-type="bibr" rid="ref10">10</xref>, <xref ref-type="bibr" rid="ref11">11</xref>). Determining RIF-resistant strains using the gene X-pert assay, a rapid and sensitive technique, is an alternative approach to detecting multidrug-resistant tuberculosis (MDR-TB) (<xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref13">13</xref>). This is because more than 90% of RIF-resistant strains are also resistant to isoniazid (INH) (<xref ref-type="bibr" rid="ref7 ref8 ref9 ref10">7&#x2013;10</xref>), and this could be explained by the rate of spontaneous mutation rate, with INH target gene having a 100-fold higher rate of mutation than RIF target gene (<xref ref-type="bibr" rid="ref14">14</xref>).</p>
<p>In Ethiopia, the burden of tuberculosis is high, and the diagnostics are woefully inadequate, with most cases being diagnosed using conventional methods. The emergence of rifampicin-resistant, combined with poor environment and living conditions, poses a significant threat to public health and safety in the country (<xref ref-type="bibr" rid="ref15">15</xref>).</p>
<p>Since 2014, the PCR assay has been used for the tuberculosis diagnostic technique in referral hospitals and regional laboratories in Ethiopia, and it is now being used in health facilities in accordance with the WHO recommendations. Sputum microscopy was the most commonly used laboratory diagnostic technique for tuberculosis. Furthermore, the magnitude of rifampicin-resistant tuberculosis has not been addressed extensively in Ethiopia using the newly developed diagnostic method PCR. As a result, the goal of this study was to provide a pooled prevalence of tuberculosis and rifampicin resistance among patients tested in Ethiopia using the PCR molecular method.</p>
<p><italic>Research question</italic>: What is the prevalence and associated factors of rifampicin-resistant tuberculosis among Ethiopian tuberculosis patients?</p>
<p><italic>Condition</italic>: Rifampicin-Resistant Tuberculosis.</p>
<p><italic>Context</italic>: Ethiopia.</p>
<p><italic>Population</italic>: All Ethiopian presumptive tuberculosis patients.</p>
</sec>
<sec sec-type="methods" id="sec6">
<title>Methods</title>
<sec id="sec7">
<title>Data source and searching strategy</title>
<p>The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guideline was used to report this review (<xref ref-type="bibr" rid="ref16">16</xref>) (<xref ref-type="supplementary-material" rid="SM1">Supplementary File1</xref>). We systematically searched five major databases (PubMed/MEDLINE, CINAHL, EMBASE, Google Scholar, and Science Direct) for studies similar with our topic of interest. Moreover, related studies were explored by searching the reference lists of eligible studies or the reference of reference. The different search strategies were applied depending on the database requirements. The two writers (MYB and SSJ) conducted the searching operations independently. Endnote X9 was used to retrieve and manage studies that were found through a systematic search. In the search, strategy different keywords/text words and medical subject headings were applied accordingly. This is an example for search strategy applied in PubMed database: &#x201C;(((((((Rifampicin [Text Word]) OR (prevalence [Text Word])) OR (associated factors [Text Word])) OR (Rifampicin resistant [Text Word])) OR (tuberculosis [MeSH Terms])) OR (Rifampicin [MeSH Terms])) AND (Ethiopia [Text Word])) AND (Ethiopia [MeSH Terms]).&#x201D; The searching strategy was performed from 28 July 2023 to 20 August 2023.</p>
</sec>
<sec id="sec8">
<title>Study selection criteria</title>
<sec id="sec9">
<title>Inclusion criteria</title>
<p>All studies conducted on rifampicin-resistant tuberculosis in Ethiopia were included.</p>
</sec>
</sec>
<sec id="sec10">
<title>Exclusion criteria</title>
<p>Those studies whose full-length were not found after two email exchanges with the corresponding authors were excluded.</p>
<p><italic>Design</italic>: A systematic review and meta-analysis.</p>
<p><italic>Publication status</italic>: All published.</p>
<p><italic>Language</italic>: English language.</p>
</sec>
<sec id="sec11">
<title>Screening procedure</title>
<p>Two authors (MYB and GMB) independently screened all titles/abstracts found in electronic databases. Disagreements were resolved through dialog. Two authors (MYB and GMB) independently screened all potentially significant full texts. Disagreements were resolved through dialog. A third author (SSJ) was consulted in the event of a disagreement.</p>
</sec>
<sec id="sec12">
<title>Data extraction process and quality assessment</title>
<p>A Microsoft Excel spreadsheet was used to create the data extraction form and extraction too. To ensure consistency, three authors (MYB, SSJ, and GMB) extracted data independently using a predefined eligibility criterion. The disagreements between authors were resolved through discussion. The study area, region, year of publication, sample size, prevalence of tuberculosis, rifampicin, and first author name were the data extracted from all included primary articles during extraction.</p>
<p>The Newcastle&#x2013;Ottawa Quality Assessment Scale (NOQAS) (<xref ref-type="bibr" rid="ref17">17</xref>) was used to evaluate the quality of the included primary studies based on study representativeness, adequate sample size, acceptable non-response rate, use of validated measurement tool, comparability of the study, description of outcome assessment, and use of appropriate statistical tests as parameters. In the quality assessment of the primary studies, those studies received seven out of ten were declared as high-quality studies (<xref ref-type="bibr" rid="ref18">18</xref>, <xref ref-type="bibr" rid="ref19">19</xref>) (<xref ref-type="supplementary-material" rid="SM1">Additional file 2</xref>).</p>
</sec>
<sec id="sec13">
<title>Outcome variable and measures</title>
<p>In this systematic review and meta-analysis, the prevalence of rifampicin-resistant tuberculosis was the main outcome of interest. We included all studies examining the existence of rifampicin -resistant tuberculosis, and the presence or absence of diagnosis of tuberculosis was performed using PCR molecular technique among suspected patients. Using a PCR machine, the incubated sample was tested for <italic>Mycobacterium tuberculosis</italic> in the primary studies. Therefore, the prevalence of rifampicin-resistant tuberculosis was determined by pooling the effect size of the primary studies. The second outcome variable for this systematic review and meta-analysis was factors associated with rifampicin-resistant tuberculosis, which was measured using the study participants&#x2019; HIV status, history of tuberculosis treatment, and sex through Meta-regression analysis.</p>
</sec>
<sec id="sec14">
<title>Data management and analysis</title>
<p>The extracted data were exported to Stata&#x2122; version 17.0 software for further analysis. The metaprop stata command was used to compute the pooled estimate. Using a binomial distribution assumption, the standard errors were calculated from the reported estimates and population denominators. The presence or absence of heterogeneity between studies was checked using Cochran&#x2019;s Q test and quantified using I-square statistics, and significant heterogeneity was found. Thus, a random-effect model based on DerSimonian and Laird was used to estimate the effect size (<xref ref-type="bibr" rid="ref20">20</xref>). Accordingly, heterogeneity was classified as low, moderate, or high when the values of I-square were 25, 50, and 75%, respectively (<xref ref-type="bibr" rid="ref19">19</xref>). Additionally, the dispersion of individual results in the forest plot was also used to evaluate the presence of heterogeneity visually. Egger&#x2019;s linear regression test at a <italic>p</italic>-value of &#x003C;0.05 was used to assess the presence of publication bias (<xref ref-type="bibr" rid="ref20">20</xref>). To identify the possible sources of heterogeneity, additional statistical analyses such as subgroup analyses, publication bias, and meta-regression were performed. We conducted a subgroup meta-analysis using study regions, sample size (above mean vs. below the mean (5418)), and study period (before 2018 vs. after 2018). Finally, the results were presented in tables and Forest plots. The presence and absence of a significant association between rifampicin-resistant and independent variables were declared using a 95% confidence interval and odds ratio.</p>
</sec>
<sec id="sec15">
<title>Patient and public involvement statement</title>
<p>Patients were not directly involved in this study. Because this systematic review and meta-analysis were conducted using previous primary studies, no study participants were recruited, and participants were not involved in the recruitment and dissemination of the findings.</p>
</sec>
</sec>
<sec sec-type="results" id="sec16">
<title>Results</title>
<sec id="sec17">
<title>Search results</title>
<p>A total of 1,664 studies were discovered through electronic databases (PubMed, EMBASE, Google Scholar, and Science Direct) and other searches (such as organizational records and websites). Approximately 1,115 studies were excluded due to duplication, 351 studies were excluded due to differences in study setting/context (<xref ref-type="bibr" rid="ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29">21&#x2013;29</xref>), 105 studies were excluded due to differences in outcome interest (<xref ref-type="bibr" rid="ref30 ref31 ref32 ref33">30&#x2013;33</xref>), and 77 studies were excluded due to differences in the study population (<xref ref-type="bibr" rid="ref27 ref28 ref29">27&#x2013;29</xref>). Finally, 16 cross-sectional studies were identified as potentially relevant for inclusion in the current meta-analysis and systematic review (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>PRISMA flow diagram of the included studies for tinea capitis among schoolchildren in Ethiopia.</p>
</caption>
<graphic xlink:href="fmed-11-1319845-g001.tif"/>
</fig>
</sec>
<sec id="sec18">
<title>Characteristics of included studies</title>
<p>According to <xref ref-type="table" rid="tab1">Table 1</xref>, approximately 16 studies with 99,429 presumptive tuberculosis patients met the inclusion criteria. This systematic review and meta-analysis included six regions and one city administration. Among them were the Amhara region (<italic>n</italic>&#x2009;=&#x2009;8) (<xref ref-type="bibr" rid="ref34 ref35 ref36">34&#x2013;36</xref>, <xref ref-type="bibr" rid="ref39">39</xref>, <xref ref-type="bibr" rid="ref42">42</xref>, <xref ref-type="bibr" rid="ref45 ref46 ref47">45&#x2013;47</xref>), the Oromia region (<italic>n</italic>&#x2009;=&#x2009;1) (<xref ref-type="bibr" rid="ref49">49</xref>), the SNNPR (<italic>n</italic>&#x2009;=&#x2009;1) (<xref ref-type="bibr" rid="ref48">48</xref>), Benishangul-Gumuz (<italic>n</italic>&#x2009;=&#x2009;1) (<xref ref-type="bibr" rid="ref44">44</xref>), Afar (<italic>n</italic>&#x2009;=&#x2009;1) (<xref ref-type="bibr" rid="ref43">43</xref>), Tigray (<italic>n</italic>&#x2009;=&#x2009;1) (<xref ref-type="bibr" rid="ref40">40</xref>), and Addis Ababa (<italic>n</italic>&#x2009;=&#x2009;3) (<xref ref-type="bibr" rid="ref37">37</xref>, <xref ref-type="bibr" rid="ref38">38</xref>, <xref ref-type="bibr" rid="ref41">41</xref>). The Amhara regional state had the study with the smallest and largest sample sizes of 170 and 26,656, respectively (<xref ref-type="table" rid="tab1">Table 1</xref>).</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Characteristics of the studies included in this systematic review and meta-analysis.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Sn</th>
<th align="left" valign="top">Authors</th>
<th align="center" valign="top">Publication year</th>
<th align="left" valign="top">Region</th>
<th align="left" valign="top">Study area</th>
<th align="center" valign="top">Sample size</th>
<th align="center" valign="top">Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">1</td>
<td align="left" valign="top">Araya Gebreyesus Wasihun et al. (<xref ref-type="bibr" rid="ref34">34</xref>)</td>
<td align="center" valign="top">2021</td>
<td align="left" valign="top">Amhara</td>
<td align="left" valign="middle">Dessie</td>
<td align="center" valign="middle">26, 656</td>
<td align="center" valign="middle">8.3</td>
</tr>
<tr>
<td align="left" valign="top">2</td>
<td align="left" valign="top">Sebsib Selfegna et al. (<xref ref-type="bibr" rid="ref35">35</xref>)</td>
<td align="center" valign="top">2022</td>
<td align="left" valign="top">Amhara</td>
<td align="left" valign="bottom">Shewa</td>
<td align="center" valign="middle">170</td>
<td align="center" valign="middle">11.2</td>
</tr>
<tr>
<td align="left" valign="top">3</td>
<td align="left" valign="top">Wondemagegn Mulu et al. (<xref ref-type="bibr" rid="ref36">36</xref>)</td>
<td align="center" valign="top">2017</td>
<td align="left" valign="top">Amhara</td>
<td align="left" valign="middle">Debre Markos</td>
<td align="center" valign="middle">505</td>
<td align="center" valign="middle">10.3</td>
</tr>
<tr>
<td align="left" valign="top">4</td>
<td align="left" valign="top">Waganeh Sinshaw et al. (<xref ref-type="bibr" rid="ref37">37</xref>)</td>
<td align="center" valign="top">2019</td>
<td align="left" valign="top">Addis Ababa</td>
<td align="left" valign="middle">Addis Ababa</td>
<td align="center" valign="middle">418</td>
<td align="center" valign="middle">6.5</td>
</tr>
<tr>
<td align="left" valign="top">5</td>
<td align="left" valign="top">Balew Arega et al. (<xref ref-type="bibr" rid="ref38">38</xref>)</td>
<td align="center" valign="top">2019</td>
<td align="left" valign="top">Addis Ababa</td>
<td align="left" valign="middle">Addis Ababa</td>
<td align="center" valign="middle">12,414</td>
<td align="center" valign="middle">9.9</td>
</tr>
<tr>
<td align="left" valign="top">6</td>
<td align="left" valign="top">Feleke Mekonnen et al. (<xref ref-type="bibr" rid="ref39">39</xref>)</td>
<td align="center" valign="top">2015</td>
<td align="left" valign="top">Amhara</td>
<td align="left" valign="middle">Metema</td>
<td align="center" valign="middle">248</td>
<td align="center" valign="middle">5.7</td>
</tr>
<tr>
<td align="left" valign="top">7</td>
<td align="left" valign="top">Tsehaye Asmelash Dejene et al. (<xref ref-type="bibr" rid="ref40">40</xref>)</td>
<td align="center" valign="top">2017</td>
<td align="left" valign="top">Tigray</td>
<td align="left" valign="middle">Adwa</td>
<td align="center" valign="middle">17,329</td>
<td align="center" valign="middle">8.7</td>
</tr>
<tr>
<td align="left" valign="top">8</td>
<td align="left" valign="top">Shambel Araya et al. (<xref ref-type="bibr" rid="ref41">41</xref>)</td>
<td align="center" valign="top">2022</td>
<td align="left" valign="top">Addiss Ababa</td>
<td align="left" valign="middle">Merkato</td>
<td align="center" valign="middle">12,685</td>
<td align="center" valign="middle">9.8</td>
</tr>
<tr>
<td align="left" valign="top">9</td>
<td align="left" valign="top">Daniel Gebretsadik et al. (<xref ref-type="bibr" rid="ref42">42</xref>)</td>
<td align="center" valign="top">2022</td>
<td align="left" valign="top">Amhara</td>
<td align="left" valign="middle">Ataye</td>
<td align="center" valign="middle">423</td>
<td align="center" valign="middle">5.3</td>
</tr>
<tr>
<td align="left" valign="top">10</td>
<td align="left" valign="top">Gebremedhn Bizayen Gebrehiwet et al. (<xref ref-type="bibr" rid="ref43">43</xref>)</td>
<td align="center" valign="top">2018</td>
<td align="left" valign="top">Afar</td>
<td align="left" valign="bottom">Dubti</td>
<td align="center" valign="middle">384</td>
<td align="center" valign="middle">4.3</td>
</tr>
<tr>
<td align="left" valign="top">11</td>
<td align="left" valign="top">Wakuman Taye et al. (<xref ref-type="bibr" rid="ref44">44</xref>)</td>
<td align="center" valign="top">2021</td>
<td align="left" valign="top">Benishangul-Gumuz</td>
<td align="left" valign="bottom">Bale zone</td>
<td align="center" valign="middle">301</td>
<td align="center" valign="middle">4.35</td>
</tr>
<tr>
<td align="left" valign="top">12</td>
<td align="left" valign="top">Awoke Derbie et al. (<xref ref-type="bibr" rid="ref45">45</xref>)</td>
<td align="center" valign="top">2016</td>
<td align="left" valign="top">Amhara</td>
<td align="left" valign="bottom">Debre Tabor</td>
<td align="center" valign="middle">1922</td>
<td align="center" valign="middle">9.3</td>
</tr>
<tr>
<td align="left" valign="top">13</td>
<td align="left" valign="top">Olifan Zewdie et al. (<xref ref-type="bibr" rid="ref33">33</xref>)</td>
<td align="center" valign="top">2020</td>
<td align="left" valign="top">Oromia</td>
<td align="left" valign="bottom">Nekemte</td>
<td align="center" valign="middle">2,300</td>
<td align="center" valign="middle">5.5</td>
</tr>
<tr>
<td align="left" valign="top">14</td>
<td align="left" valign="top">Kefyalew N Jaleta et al. (<xref ref-type="bibr" rid="ref46">46</xref>)</td>
<td align="center" valign="top">2017</td>
<td align="left" valign="top">Amhara</td>
<td align="left" valign="bottom">Gondar</td>
<td align="center" valign="middle">1820</td>
<td align="center" valign="middle">12</td>
</tr>
<tr>
<td align="left" valign="top">15</td>
<td align="left" valign="top">Tesfaye Andualem Demissie (<xref ref-type="bibr" rid="ref47">47</xref>)</td>
<td align="center" valign="top">2021</td>
<td align="left" valign="top">Amhara</td>
<td align="left" valign="bottom">Motta</td>
<td align="center" valign="middle">4,109</td>
<td align="center" valign="middle">4.3</td>
</tr>
<tr>
<td align="left" valign="top">16</td>
<td align="left" valign="top">Kuma Diriba et al. (<xref ref-type="bibr" rid="ref48">48</xref>)</td>
<td align="center" valign="top">2021</td>
<td align="left" valign="top">SNNP</td>
<td align="left" valign="bottom">Gedeo</td>
<td align="center" valign="middle">17,745</td>
<td align="center" valign="middle">5.1</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec19">
<title>The pooled prevalence of rifampicin-resistant tuberculosis</title>
<p>By molecular detection, the overall prevalence of <italic>Mycobacterium tuberculosis</italic> was 14.9% (95% CI: 13.34, 16.46), approximately 7.48% (95% CI: 6.30, 8.66) showed rifampicin resistance in Ethiopia. When we looked at it by region, Addis Ababa city administration had the highest prevalence of rifampicin-resistant <italic>Mycobacterium tuberculosis</italic> (9.49, 95% CI: 8.62, 10.36), followed by Amhara regional state (8.16, 95% CI: 6.18, 10.13) (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>The pooled prevalence of rifampicin in Ethiopia.</p>
</caption>
<graphic xlink:href="fmed-11-1319845-g002.tif"/>
</fig>
</sec>
<sec id="sec20">
<title>Subgroup meta-analysis</title>
<p>The random-effect meta-regression model was used to identify the source of heterogeneity by conducting subgroup meta-analysis while taking into account study region, sample size, and publication year. As a result, there are no sources of heterogeneity identified using subgroup meta-analysis. However, there is strong evidence supporting the existence of heterogeneity, publication year before 2018 I<sup>2</sup> =&#x2009;88.4 with a <italic>p</italic>-value of 0.0001 and after I<sup>2</sup>&#x2009;=&#x2009;98.2 with a <italic>p</italic>-value of &#x003C;0.0001 (<xref ref-type="fig" rid="fig3">Figure 3</xref>), and the sample size greater than the mean (&#x003E;5,418) I<sup>2</sup> =&#x2009;98.6 and less than the mean sample size (&#x003C; 5,418) I<sup>2</sup>&#x2009;=&#x2009;70.0 with a <italic>p</italic>-value of &#x003C;0.0001 (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Subgroup analysis using sample.</p>
</caption>
<graphic xlink:href="fmed-11-1319845-g003.tif"/>
</fig>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Subgroup analysis using the publication year.</p>
</caption>
<graphic xlink:href="fmed-11-1319845-g004.tif"/>
</fig>
</sec>
<sec id="sec21">
<title>Meta-regression</title>
<p>In random-effects meta-regression, the year of publication and sample size were used as covariates. The study found that sample size (<italic>p</italic>&#x2009;=&#x2009;0.34) and publication year (<italic>p</italic>&#x2009;=&#x2009;0.22) did not affect heterogeneity (heterogeneity was not explained by sample size or publication year) (<xref ref-type="table" rid="tab2">Table 2</xref>).</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Meta-regression using year of publication and sample size for rifampicin-resistant <italic>Mycobacterium tuberculosis</italic> in Ethiopia.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">logrr</th>
<th align="center" valign="top">Coefficient</th>
<th align="center" valign="top">Std. err.</th>
<th align="center" valign="top"><italic>t</italic></th>
<th align="center" valign="top">P&#x2009;&#x003E;&#x2009;|t|</th>
<th align="center" valign="top">[95% conf. interval]</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Year of publication</td>
<td align="center" valign="top">0.00</td>
<td align="center" valign="top">0.01</td>
<td align="center" valign="top">0.99</td>
<td align="center" valign="top">0.34</td>
<td align="center" valign="top">&#x2212;0.01,0 0.01</td>
</tr>
<tr>
<td align="left" valign="top">Sample size</td>
<td align="center" valign="top">&#x2212;0.40</td>
<td align="center" valign="top">0.31</td>
<td align="center" valign="top">&#x2212;1.29</td>
<td align="center" valign="top">0.22</td>
<td align="center" valign="top">&#x2212;1.06,0.27</td>
</tr>
<tr>
<td align="left" valign="top">Constant</td>
<td align="center" valign="top">815.07</td>
<td align="center" valign="top">624.02</td>
<td align="center" valign="top">1.31</td>
<td align="center" valign="top">0.21</td>
<td align="center" valign="top">&#x2212;533.16, 259.34</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec22">
<title>Publication bias (bias detection)</title>
<p>The scatter plots were symmetrical, and the funnel is wide at the bottom and narrow at the top, which indicates that the small study had no effects (free of publication bias) on the heterogeneity of rifampicin-resistant <italic>Mycobacterium tuberculosis</italic> (<xref ref-type="fig" rid="fig5">Figure 5</xref>), and then, we used the Egger linear regression test to objectively confirm the existence of publication bias. As a result, no statistically significant publication bias (<italic>p</italic>&#x2009;=&#x2009;0.0001) was observed (<xref ref-type="table" rid="tab3">Table 3</xref>).</p>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p>The funnel plot of rifampicin resistance in Ethiopia.</p>
</caption>
<graphic xlink:href="fmed-11-1319845-g005.tif"/>
</fig>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>The table to check the publication bias objectively.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Std_Eff</th>
<th align="center" valign="top">Coefficient</th>
<th align="center" valign="top">Std. err.</th>
<th align="center" valign="top"><italic>t</italic></th>
<th align="center" valign="top">P&#x2009;&#x003E;&#x2009;|t|</th>
<th align="center" valign="top">[95% conf. interval]</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Slope</td>
<td align="char" valign="top" char=".">7.39</td>
<td align="char" valign="top" char=".">0.88</td>
<td align="char" valign="top" char=".">8.36</td>
<td align="char" valign="top" char=".">0.000</td>
<td align="char" valign="top" char=".">5.499.28</td>
</tr>
<tr>
<td align="left" valign="top">Bias</td>
<td align="char" valign="top" char=".">0.37</td>
<td align="char" valign="top" char=".">2.66</td>
<td align="char" valign="top" char=".">0.14</td>
<td align="char" valign="top" char=".">0.89</td>
<td align="char" valign="top" char=".">&#x2212;5.336.06</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec23">
<title>Factors associated with rifampicin-resistant tuberculosis</title>
<p>Factors associated with rifampicin-resistant tuberculosis were determined using sex (including 10 studies) (<xref ref-type="bibr" rid="ref38 ref39 ref40 ref41">38&#x2013;41</xref>, <xref ref-type="bibr" rid="ref46">46</xref>, <xref ref-type="bibr" rid="ref47">47</xref>), history of tuberculosis treatment (including 10 studies) (<xref ref-type="bibr" rid="ref38 ref39 ref40 ref41">38&#x2013;41</xref>, <xref ref-type="bibr" rid="ref46">46</xref>, <xref ref-type="bibr" rid="ref47">47</xref>), and current HIV serostatus (including 10 studies) (<xref ref-type="bibr" rid="ref38 ref39 ref40 ref41">38&#x2013;41</xref>, <xref ref-type="bibr" rid="ref46">46</xref>, <xref ref-type="bibr" rid="ref47">47</xref>). Finally, rifampicin-resistant tuberculosis was significantly associated with having a history of tuberculosis treatment and living with HIV.</p>
<p>Being male had a 1.04 (95% CI: 0.87, 1.24), and living with HIV (being positive for HIV) had a 1.39 (95%CI: 1.13, 1.72).</p>
<p>The odds of developing rifampicin-resistant tuberculosis were 1.39 (95% CI: 1.13, 1.72) times higher among TB patients who have HIV-positive coinfection compared with their counterparts (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption>
<p>Meta-regression for a history of tuberculosis treatment.</p>
</caption>
<graphic xlink:href="fmed-11-1319845-g006.tif"/>
</fig>
<p>The odds of developing rifampicin-resistant tuberculosis among presumptive tuberculosis patients who had a history of tuberculosis treatment were 2.05 (95% CI: 1.34, 3.15) times higher when compared with those study participants who had no previous tuberculosis treatment (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p>
<fig position="float" id="fig7">
<label>Figure 7</label>
<caption>
<p>Meta-regression for coinfection of HIV in Ethiopia.</p>
</caption>
<graphic xlink:href="fmed-11-1319845-g007.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="sec24">
<title>Discussion</title>
<p>This systematic review and meta-analysis incorporated 16 studies conducted between 2015 and 2022 with 99,429 tuberculosis patients. The sample size of each study ranged from 170 to 26,656 study participants. The study participants were selected using either a simple or systematic random sampling approach in each study.</p>
<p>By molecular detection, the overall pooled prevalence of TB was 14.9% (95% CI: 13.34, 16.46), and of these, 7.48% (95% CI: 6.30, 8.66) was the pooled prevalence of RR TB in Ethiopia. It means half of the TB patients in Ethiopia developed RR which is high to achieving end-TB- strategy by 2030 because of how we can achieve zero morbidity and mortality in the presence of a 3.0% secondary attack rate (<xref ref-type="bibr" rid="ref50">50</xref>) and 39% mortality rate (<xref ref-type="bibr" rid="ref51">51</xref>) with 7.48% existence of RR TB is keeping on. This could be due to the fact that TB patients delayed anti-TB drug initiation as well as no more close follow-up for supervising daily pill intake allowing poor adherence to their medication and resulting the comorbidities, mutated bacterial multiplication, immune deterioration, disease progression, and finally causing RR TB.</p>
<p>The prevalence of this study was higher than the prevalence of a study conducted in Botswana and Nigeria, which were 5.4 and 6%, respectively (<xref ref-type="bibr" rid="ref52">52</xref>, <xref ref-type="bibr" rid="ref53">53</xref>). This could be because, in the current study, more study participants had TB-HIV coinfection, previous history of TB treatment (especially default), and less media exposure than what is happening in Nigeria and Botswana. As this study, finding supports, previous history of TB treatment and having TB-HIV coinfection were the significantly associated factors for developing RR TB. Therefore, the greater pooled prevalence of RR TB in Ethiopia might be a result.</p>
<p>In this study, the prevalence of RR tuberculosis was higher than the study findings in Botswana and Nigeria, which were 5.4 and 6%, respectively (<xref ref-type="bibr" rid="ref52">52</xref>, <xref ref-type="bibr" rid="ref53">53</xref>). This could be because the current study had more study participants than the previous one, and as we know, a difference in the number of susceptible cases can affect the prevalence, which is why the prevalence of rifampicin resistance is higher in Ethiopia than in Botswana and Nigeria.</p>
<p>The odds of developing RRTB were 1.39 (95% CI: 1.13, 1.72) times higher among study participants who had TB-HIV coinfection than those who had not TB-HIV coinfection. This finding was in line with the study conducted in Nigeria (<xref ref-type="bibr" rid="ref54">54</xref>). This might be due to the fact that study participants having TB-HIV coinfection may have overlapping of drug (toxicities, side effects), burden of pills, and drug&#x2013;drug interaction, as well as HIV weakens the immune system, letting poor RIF adherence and resulting high mutated bacilli multiplication and disease progression and finally causing RR TB (<xref ref-type="bibr" rid="ref55">55</xref>). That is why those study participants having TB-HIV coinfection had more chance of developing RR TB than their counterparts.</p>
<p>The odds of developing RR TB among study participants who had a history of TB treatment were 2.05 (95% CI: 1.34, 3.15) times higher than those study participants who had no previous TB treatment. This could be the fact that the history of prior treatment focusing on default letting bacilli strains adapt RIF which provides the chance of bacilli strains mutating (<xref ref-type="bibr" rid="ref56">56</xref>) and multiplying and finally causing RR TB.</p>
<p>The findings of this research play a crucial role in shaping public health policies, treatment guidelines, and future research directions to effectively address the challenges posed by drug-resistant tuberculosis strains.</p>
<p>It impacts public health policies by informing the development of public health policies aimed at controlling the spread of rifampicin-resistant tuberculosis, particularly drug-resistant tuberculosis at large. For example, public health officials can implement targeted interventions to reduce HIV-TB coinfection and previous TB treatment history and prevent the emergence of drug-resistant strains. Additionally, the findings can help guide the allocation of resources for surveillance, diagnostic testing, and treatment programs for rifampicin-resistant tuberculosis.</p>
<p>The findings of this research can also impact treatment guidelines for rifampicin-resistant tuberculosis. By identifying specific genetic mutations or markers associated with rifampicin resistance, clinicians can use molecular tests to quickly and accurately diagnose drug-resistant strains. This information can help healthcare providers tailor treatment regimens to target the specific resistance mechanisms present in individual patients, leading to more effective and personalized treatment strategies. Finally, the findings of this research may highlight gaps in current knowledge that warrant further investigation, such as understanding the mechanisms underlying the development of drug resistance or exploring potential interventions to mitigate the spread of drug-resistant strains.</p>
</sec>
<sec id="sec25">
<title>Recommendation</title>
<p>Our recommendation regarding to one out of every twenty-five TB patients experiencing RR TB.</p>
<list list-type="simple">
<list-item><p><italic>Enhanced Screening</italic>: Implementing improved screening techniques to detect persons with RR tuberculosis early in their disease progression. This might include routine medication susceptibility testing for all TB patients in order to discover rifampicin resistance early on and commence appropriate treatment.</p></list-item>
<list-item><p><italic>Capacity Building</italic>: Strengthening laboratory capacity to perform drug susceptibility testing for rifampicin and other anti-TB drugs. This will ensure timely and accurate diagnosis of drug-resistant TB cases, enabling healthcare providers to deliver targeted treatment interventions.</p></list-item>
<list-item><p><italic>Patient Education</italic>: Providing comprehensive education to TB patients about the importance of completing treatment, adherence to medication regimens, and the risks associated with drug resistance. Empowering patients with knowledge can improve treatment outcomes and reduce the spread of resistant strains.</p></list-item>
<list-item><p><italic>Contact Tracing</italic>: Implementing robust contact tracing programs to identify individuals who may have been exposed to RR TB cases. This will help prevent further transmission of drug-resistant strains and facilitate early detection and treatment of latent infections.</p></list-item>
</list>
<sec id="sec26">
<title>Our recommendation depending on the TB-HIV coinfection</title>
<list list-type="simple">
<list-item><p><italic>Integrated Screening and Management</italic>: Implementing integrated screening programs to detect people with tuberculosis and HIV infections early on, ensuring quick diagnosis and appropriate treatment.</p></list-item>
<list-item><p><italic>Optimized Treatment Regimens</italic>: Individuals with TB-HIV coinfection should have treatment regimens tailored to successfully address both disorders through combination therapy that takes into account potential drug interactions between anti-TB medications and antiretroviral therapies used to treat HIV.</p></list-item>
<list-item><p><italic>Regular Monitoring</italic>: Individuals with TB-HIV coinfection should be regularly monitored throughout their treatment to assess response to medication, detect early indicators of treatment failure or drug resistance, and change treatment plans as appropriate.</p></list-item>
<list-item><p><italic>Adherence Support</italic>: Providing comprehensive support services to promote treatment adherence among individuals with TB-HIV coinfection, including counseling, education on the importance of completing treatment regimens, and addressing any barriers to adherence that may arise due to the complexity of managing both conditions concurrently.</p></list-item>
<list-item><p><italic>Infection Control Measures</italic>: Strengthening laboratory capacity for drug susceptibility testing of rifampicin and other anti-TB drugs. This would enable the timely and accurate diagnosis of drug-resistant tuberculosis cases, allowing healthcare providers to give tailored treatment strategies.</p></list-item>
<list-item><p><italic>Research and Surveillance</italic>: Conducting additional research to have a better understanding on the impact of TB-HIV coinfection on the development of rifampicin resistance, as well as to look into novel approaches to improving outcomes for people affected by both conditions, such as evaluating new diagnostic tools or developing targeted interventions to address specific challenges associated with dual infection.</p></list-item>
</list>
</sec>
<sec id="sec27">
<title>Our recommendation focusing on having history of previous TB treatment</title>
<list list-type="simple">
<list-item><p><italic>Drug Susceptibility Testing</italic>: Conducting drug susceptibility testing for individuals with a history of previous TB treatment to identify any drug-resistant strains early on, which will help guide the selection of appropriate treatment regimens and avoid the use of ineffective drugs.</p></list-item>
<list-item><p><italic>Individualized Treatment Plans</italic>: Developing individualized treatment plans for individuals with a history of previous TB treatment and rifampicin resistance. It may be by using alternative anti-TB medications or combination therapy based on the results of drug susceptibility testing to ensure effective treatment.</p></list-item>
<list-item><p><italic>Close Monitoring</italic>: Monitoring individuals with a history of previous TB treatment and rifampicin resistance closely throughout their treatment to assess response to therapy, detect any signs of treatment failure or drug resistance early, and adjust treatment plans as needed.</p></list-item>
<list-item><p><italic>Adherence Support</italic>: Providing comprehensive support services to promote treatment adherence among individuals with a history of previous TB treatment and rifampicin resistance. This can include counseling, education on the importance of completing treatment regimens, and addressing any barriers to adherence that may arise due to previous treatment experiences.</p></list-item>
<list-item><p><italic>Health System Strengthening</italic>: Strengthening health systems to improve TB control programs, enhancing surveillance mechanisms for monitoring drug resistance, and ensuring access to quality diagnostic tools and effective treatments for individuals with a history of previous TB treatment and rifampicin resistance.</p></list-item>
</list>
</sec>
</sec>
<sec sec-type="conclusions" id="sec28">
<title>Conclusion</title>
<p>RR TB was one of the emerging challenges among TB patients, which affected approximately one out of every twenty-five TB patients. Having TB-HIV coinfection and history of previous anti-TB treatment were the significant factors associated with RR tuberculosis.</p>
</sec>
<sec sec-type="data-availability" id="sec29">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="author-contributions" id="sec30">
<title>Author contributions</title>
<p>MB: Conceptualization, Data curation, Investigation, Methodology, Software, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. GB: Conceptualization, Data curation, Investigation, Methodology, Software, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. SJ: Conceptualization, Formal analysis, Investigation, Project administration, Resources, Software, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec31">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<ack>
<p>The authors thank the primary authors of the included studies for their contribution to the field of rifampicin resistance and their response through email.</p>
</ack>
<sec sec-type="COI-statement" id="sec32">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec33">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fmed.2024.1319845/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fmed.2024.1319845/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.DOCX" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Murphy</surname> <given-names>C</given-names></name> <name><surname>Bernardo</surname> <given-names>J</given-names></name></person-group>: <source>Patient education: Tuberculosis (Beyond the Basics)</source>. (<year>n.d.</year>).</citation></ref>
<ref id="ref2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chheng</surname> <given-names>P</given-names></name> <name><surname>Tamhane</surname> <given-names>A</given-names></name> <name><surname>Natpratan</surname> <given-names>C</given-names></name> <name><surname>Tan</surname> <given-names>V</given-names></name> <name><surname>Lay</surname> <given-names>V</given-names></name> <name><surname>Sar</surname> <given-names>B</given-names></name> <etal/></person-group>. <article-title>Pulmonary tuberculosis among patients visiting a voluntary confidential counseling and testing center, Cambodia</article-title>. <source>Int J Tuberc Lung Dis</source>. (<year>2008</year>) <volume>12</volume>:<fpage>S54</fpage>&#x2013;<lpage>62</lpage>.</citation></ref>
<ref id="ref3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname> <given-names>DL</given-names></name> <name><surname>Bustreo</surname> <given-names>F</given-names></name> <name><surname>Raviglione</surname> <given-names>MC</given-names></name></person-group>. <article-title>Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project</article-title>. <source>Clin Infect Dis</source>. (<year>1997</year>) <volume>24</volume>:<fpage>S121</fpage>&#x2013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1093/clinids/24.Supplement_1.S121</pub-id></citation></ref>
<ref id="ref4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname> <given-names>T</given-names></name> <name><surname>Cegielski</surname> <given-names>P</given-names></name> <name><surname>Akksilp</surname> <given-names>S</given-names></name> <name><surname>Asencios</surname> <given-names>L</given-names></name> <name><surname>Caoili</surname> <given-names>JC</given-names></name> <name><surname>Cho</surname> <given-names>S-N</given-names></name> <etal/></person-group>. <article-title>Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study</article-title>. <source>Lancet</source>. (<year>2012</year>) <volume>380</volume>:<fpage>1406</fpage>&#x2013;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60734-X</pub-id>, PMID: <pub-id pub-id-type="pmid">22938757</pub-id></citation></ref>
<ref id="ref5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><collab id="coll1">Group WPPLW</collab></person-group>. <article-title>Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis</article-title>. <source>Lancet Infect Dis</source>. (<year>2018</year>) <volume>18</volume>:<fpage>318</fpage>&#x2013;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30753-3</pub-id></citation></ref>
<ref id="ref6"><label>6.</label><citation citation-type="other"><person-group person-group-type="author"><collab id="coll2">WHO: World Health Organization</collab></person-group>. <source>Global Tuberculosis Report</source> (<year>2016</year>).</citation></ref>
<ref id="ref7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Espinal</surname> <given-names>MA</given-names></name> <name><surname>Kim</surname> <given-names>SJ</given-names></name> <name><surname>Suarez</surname> <given-names>PG</given-names></name> <name><surname>Kam</surname> <given-names>KM</given-names></name> <name><surname>Khomenko</surname> <given-names>AG</given-names></name> <name><surname>Migliori</surname> <given-names>GB</given-names></name> <etal/></person-group>. <article-title>Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries</article-title>. <source>JAMA</source>. (<year>2000</year>) <volume>283</volume>:<fpage>2537</fpage>&#x2013;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.283.19.2537</pub-id></citation></ref>
<ref id="ref8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joh</surname> <given-names>JS</given-names></name> <name><surname>Hong</surname> <given-names>HC</given-names></name> <name><surname>Jeong</surname> <given-names>IA</given-names></name> <name><surname>Chin</surname> <given-names>BS</given-names></name> <name><surname>Yang</surname> <given-names>HJ</given-names></name> <name><surname>Choi</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>Proportion of multidrug-resistant tuberculosis in human immunodeficiency virus/<italic>mycobacterium tuberculosis</italic> co-infected patients in Korea</article-title>. <source>J Korean Med Sci</source>. (<year>2012</year>) <volume>27</volume>:<fpage>1143</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.3346/jkms.2012.27.10.1143</pub-id>, PMID: <pub-id pub-id-type="pmid">23091309</pub-id></citation></ref>
<ref id="ref9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Telenti</surname> <given-names>A</given-names></name> <name><surname>Imboden</surname> <given-names>P</given-names></name> <name><surname>Marchesi</surname> <given-names>F</given-names></name> <name><surname>Matter</surname> <given-names>L</given-names></name> <name><surname>Schopfer</surname> <given-names>K</given-names></name> <name><surname>Bodmer</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>Detection of rifampicin-resistance mutations in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Lancet</source>. (<year>1993</year>) <volume>341</volume>:<fpage>647</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0140-6736(93)90417-F</pub-id></citation></ref>
<ref id="ref10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchison</surname> <given-names>D</given-names></name> <name><surname>Nunn</surname> <given-names>A</given-names></name></person-group>. <article-title>Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis</article-title>. <source>Am Rev Respir Dis</source>. (<year>1986</year>) <volume>133</volume>:<fpage>423</fpage>&#x2013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1164/arrd.1986.133.3.423</pub-id>, PMID: <pub-id pub-id-type="pmid">2420242</pub-id></citation></ref>
<ref id="ref11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyssonnier</surname> <given-names>V</given-names></name> <name><surname>Bui</surname> <given-names>TV</given-names></name> <name><surname>Veziris</surname> <given-names>N</given-names></name> <name><surname>Jarlier</surname> <given-names>V</given-names></name> <name><surname>Robert</surname> <given-names>J</given-names></name></person-group>. <article-title>Rifampicin mono-resistant tuberculosis in France: a 2005&#x2013;2010 retrospective cohort analysis</article-title>. <source>BMC Infect Dis</source>. (<year>2014</year>) <volume>14</volume>:<fpage>1</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2334-14-18</pub-id></citation></ref>
<ref id="ref12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname> <given-names>L</given-names></name> <name><surname>Albert</surname> <given-names>H</given-names></name> <name><surname>Gilpin</surname> <given-names>C</given-names></name> <name><surname>Alexander</surname> <given-names>H</given-names></name> <name><surname>DeGruy</surname> <given-names>K</given-names></name> <name><surname>Stevens</surname> <given-names>W</given-names></name></person-group>. <article-title>Multicenter feasibility study to assess external quality assessment panels for Xpert MTB/RIF assay in South Africa</article-title>. <source>J Clin Microbiol</source>. (<year>2014</year>) <volume>52</volume>:<fpage>2493</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JCM.03533-13</pub-id>, PMID: <pub-id pub-id-type="pmid">24789182</pub-id></citation></ref>
<ref id="ref13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belay</surname> <given-names>M</given-names></name> <name><surname>Bjune</surname> <given-names>G</given-names></name> <name><surname>Abebe</surname> <given-names>F</given-names></name></person-group>. <article-title>Prevalence of tuberculosis, HIV, and TB-HIV co-infection among pulmonary tuberculosis suspects in a predominantly pastoralist area, Northeast Ethiopia</article-title>. <source>Glob Health Action</source>. (<year>2015</year>) <volume>8</volume>:<fpage>27949</fpage>. doi: <pub-id pub-id-type="doi">10.3402/gha.v8.27949</pub-id>, PMID: <pub-id pub-id-type="pmid">26689454</pub-id></citation></ref>
<ref id="ref14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biadglegne</surname> <given-names>F</given-names></name> <name><surname>Sack</surname> <given-names>U</given-names></name> <name><surname>Rodloff</surname> <given-names>AC</given-names></name></person-group>. <article-title>Multidrug-resistant tuberculosis in Ethiopia: efforts to expand diagnostic services, treatment and care</article-title>. <source>Antimicrob Resist Infect Control</source>. (<year>2014</year>) <volume>3</volume>:<fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1186/2047-2994-3-31</pub-id></citation></ref>
<ref id="ref15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gelaw</surname> <given-names>YA</given-names></name> <name><surname>Assefa</surname> <given-names>Y</given-names></name> <name><surname>Magalhaes</surname> <given-names>RJS</given-names></name> <name><surname>Demissie</surname> <given-names>M</given-names></name> <name><surname>Tadele</surname> <given-names>W</given-names></name> <name><surname>Dhewantara</surname> <given-names>PW</given-names></name> <etal/></person-group>. <article-title>TB and HIV epidemiology and collaborative service: evidence from Ethiopia, 2011&#x2013;2015</article-title>. <source>HIV/AIDS</source>. (<year>2020</year>) <volume>12</volume>:<fpage>839</fpage>&#x2013;<lpage>47</lpage>. doi: <pub-id pub-id-type="doi">10.2147/HIV.S284722</pub-id></citation></ref>
<ref id="ref16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rethlefsen</surname> <given-names>ML</given-names></name> <name><surname>Kirtley</surname> <given-names>S</given-names></name> <name><surname>Waffenschmidt</surname> <given-names>S</given-names></name> <name><surname>Ayala</surname> <given-names>AP</given-names></name> <name><surname>Moher</surname> <given-names>D</given-names></name> <name><surname>Page</surname> <given-names>MJ</given-names></name> <etal/></person-group>. <article-title>PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews</article-title>. <source>Syst Rev</source>. (<year>2021</year>) <volume>10</volume>:<fpage>1</fpage>&#x2013;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s13643-020-01542-z</pub-id></citation></ref>
<ref id="ref17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fazel</surname> <given-names>S</given-names></name> <name><surname>Khosla</surname> <given-names>V</given-names></name> <name><surname>Doll</surname> <given-names>H</given-names></name> <name><surname>Geddes</surname> <given-names>J</given-names></name></person-group>. <article-title>The prevalence of mental disorders among the homeless in western countries: systematic review and meta-regression analysis</article-title>. <source>PLoS Med</source>. (<year>2008</year>) <volume>5</volume>:<fpage>e225</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pmed.0050225</pub-id>, PMID: <pub-id pub-id-type="pmid">19053169</pub-id></citation></ref>
<ref id="ref18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname> <given-names>MM</given-names></name> <name><surname>Iqbal</surname> <given-names>U</given-names></name> <name><surname>Walther</surname> <given-names>B</given-names></name> <name><surname>Atique</surname> <given-names>S</given-names></name> <name><surname>Dubey</surname> <given-names>NK</given-names></name> <name><surname>Nguyen</surname> <given-names>P-A</given-names></name> <etal/></person-group>. <article-title>Li Y-CJ, Shabbir S-A: benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis</article-title>. <source>Neuroepidemiology</source>. (<year>2016</year>) <volume>47</volume>:<fpage>181</fpage>&#x2013;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000454881</pub-id>, PMID: <pub-id pub-id-type="pmid">28013304</pub-id></citation></ref>
<ref id="ref19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leshargie</surname> <given-names>CT</given-names></name> <name><surname>Alebel</surname> <given-names>A</given-names></name> <name><surname>Kibret</surname> <given-names>GD</given-names></name> <name><surname>Birhanu</surname> <given-names>MY</given-names></name> <name><surname>Mulugeta</surname> <given-names>H</given-names></name> <name><surname>Malloy</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>The impact of peer pressure on cigarette smoking among high school and university students in Ethiopia: a systemic review and meta-analysis</article-title>. <source>PLoS One</source>. (<year>2019</year>) <volume>14</volume>:<fpage>e0222572</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0222572</pub-id>, PMID: <pub-id pub-id-type="pmid">31603930</pub-id></citation></ref>
<ref id="ref20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname> <given-names>R</given-names></name> <name><surname>Laird</surname> <given-names>N</given-names></name></person-group>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source>. (<year>1986</year>) <volume>7</volume>:<fpage>177</fpage>&#x2013;<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0197-2456(86)90046-2</pub-id></citation></ref>
<ref id="ref21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kigozi</surname> <given-names>E</given-names></name> <name><surname>Kasule</surname> <given-names>GW</given-names></name> <name><surname>Musisi</surname> <given-names>K</given-names></name> <name><surname>Lukoye</surname> <given-names>D</given-names></name> <name><surname>Kyobe</surname> <given-names>S</given-names></name> <name><surname>Katabazi</surname> <given-names>FA</given-names></name> <etal/></person-group>. <article-title>Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in <italic>Mycobacterium tuberculosis</italic> isolates from Uganda</article-title>. <source>PLoS One</source>. (<year>2018</year>) <volume>13</volume>:<fpage>e0198091</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0198091</pub-id>, PMID: <pub-id pub-id-type="pmid">29847567</pub-id></citation></ref>
<ref id="ref22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adejumo</surname> <given-names>OA</given-names></name> <name><surname>Olusola-Faleye</surname> <given-names>B</given-names></name> <name><surname>Adepoju</surname> <given-names>V</given-names></name> <name><surname>Bowale</surname> <given-names>A</given-names></name> <name><surname>Adesola</surname> <given-names>S</given-names></name> <name><surname>Falana</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria</article-title>. <source>Afr Health Sci</source>. (<year>2018</year>) <volume>18</volume>:<fpage>472</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.4314/ahs.v18i3.2</pub-id>, PMID: <pub-id pub-id-type="pmid">30602977</pub-id></citation></ref>
<ref id="ref23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gautam</surname> <given-names>PB</given-names></name> <name><surname>Mishra</surname> <given-names>A</given-names></name> <name><surname>Kumar</surname> <given-names>S</given-names></name></person-group>. <article-title>Prevalence of rifampicin resistant mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients in eastern Uttar Pradesh: a cross sectional study</article-title>. <source>Int J Community Med Public Health</source>. (<year>2018</year>) <volume>5</volume>:<fpage>2271</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.18203/2394-6040.ijcmph20182039</pub-id></citation></ref>
<ref id="ref24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weltman</surname> <given-names>AC</given-names></name> <name><surname>Righi</surname> <given-names>SP</given-names></name> <name><surname>DiFerdinando</surname> <given-names>GT</given-names> <suffix>Jr</suffix></name> <name><surname>Jovell</surname> <given-names>RJ</given-names></name> <name><surname>Driscoll</surname> <given-names>JR</given-names></name></person-group>. <article-title>Rifampicin-resistant <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Lancet</source>. (<year>1995</year>) <volume>345</volume>:<fpage>1513</fpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(95)91074-3</pub-id></citation></ref>
<ref id="ref25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Svensson</surname> <given-names>E</given-names></name> <name><surname>Folkvardsen</surname> <given-names>DB</given-names></name> <name><surname>Rasmussen</surname> <given-names>EM</given-names></name> <name><surname>Lillebaek</surname> <given-names>T</given-names></name></person-group>. <article-title>Detection of <italic>Mycobacterium tuberculosis</italic> complex in pulmonary and extrapulmonary samples with the FluoroType MTBDR assay</article-title>. <source>Clin Microbiol Infect</source>. (<year>2021</year>) <volume>27</volume>:<fpage>1514.e1</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmi.2020.12.020</pub-id></citation></ref>
<ref id="ref26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collantes</surname> <given-names>J</given-names></name> <name><surname>Solari</surname> <given-names>FB</given-names></name> <name><surname>Rigouts</surname> <given-names>L</given-names></name></person-group>. <article-title>Rapid detection of <italic>Mycobacterium tuberculosis</italic> strains resistant to isoniazid and/or rifampicin: standardization of multiplex polymerase chain reaction analysis</article-title>. <source>Am J Trop Med Hyg</source>. (<year>2016</year>) <volume>95</volume>:<fpage>1257</fpage>&#x2013;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.4269/ajtmh.16-0120</pub-id>, PMID: <pub-id pub-id-type="pmid">27928076</pub-id></citation></ref>
<ref id="ref27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Knegt</surname> <given-names>GJ</given-names></name> <name><surname>Bruning</surname> <given-names>O</given-names></name> <name><surname>ten Kate</surname> <given-names>MT</given-names></name> <name><surname>de Jong</surname> <given-names>M</given-names></name> <name><surname>van Belkum</surname> <given-names>A</given-names></name> <name><surname>Endtz</surname> <given-names>HP</given-names></name> <etal/></person-group>. <article-title>Rifampicin-induced transcriptome response in rifampicin-resistant <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Tuberculosis (Edinb)</source>. (<year>2013</year>) <volume>93</volume>:<fpage>96</fpage>&#x2013;<lpage>101</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tube.2012.10.013</pub-id>, PMID: <pub-id pub-id-type="pmid">23182912</pub-id></citation></ref>
<ref id="ref28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llerena</surname> <given-names>C</given-names></name> <name><surname>Medina</surname> <given-names>R</given-names></name></person-group>. <article-title>Description of <italic>Mycobacterium tuberculosis</italic> mutations conferring resistance to rifampicin and isoniazid detected by GenoType&#x00AE; MTBDRplus V.2 in Colombia</article-title>. <source>Biomedica</source>. (<year>2017</year>) <volume>37</volume>:<fpage>28</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.7705/biomedica.v37i1.3174</pub-id>, PMID: <pub-id pub-id-type="pmid">28527245</pub-id></citation></ref>
<ref id="ref29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loots du</surname> <given-names>T</given-names></name></person-group>. <article-title>New insights into the survival mechanisms of rifampicin-resistant <italic>Mycobacterium tuberculosis</italic></article-title>. <source>J Antimicrob Chemother</source>. (<year>2016</year>) <volume>71</volume>:<fpage>655</fpage>&#x2013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkv406</pub-id></citation></ref>
<ref id="ref30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mekonnen</surname> <given-names>D</given-names></name> <name><surname>Admassu</surname> <given-names>A</given-names></name> <name><surname>Mulu</surname> <given-names>W</given-names></name> <name><surname>Amor</surname> <given-names>A</given-names></name> <name><surname>Benito</surname> <given-names>A</given-names></name> <name><surname>Gelaye</surname> <given-names>W</given-names></name> <etal/></person-group>. <article-title>Multidrug-resistant and heteroresistant mycobacterium tuberculosis and associated gene mutations in Ethiopia</article-title>. <source>Int J Infect Dis</source>. (<year>2015</year>) <volume>39</volume>:<fpage>34</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2015.06.013</pub-id>, PMID: <pub-id pub-id-type="pmid">26119857</pub-id></citation></ref>
<ref id="ref31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bedewi</surname> <given-names>Z</given-names></name> <name><surname>Mekonnen</surname> <given-names>Y</given-names></name> <name><surname>Worku</surname> <given-names>A</given-names></name> <name><surname>Medhin</surname> <given-names>G</given-names></name> <name><surname>Zewde</surname> <given-names>A</given-names></name> <name><surname>Yimer</surname> <given-names>G</given-names></name> <etal/></person-group>. <article-title><italic>Mycobacterium tuberculosis</italic> in Central Ethiopia: drug sensitivity patterns and association with genotype</article-title>. <source>New Microbes New Infect</source>. (<year>2017</year>) <volume>17</volume>:<fpage>69</fpage>&#x2013;<lpage>74</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nmni.2017.02.003</pub-id>, PMID: <pub-id pub-id-type="pmid">28377803</pub-id></citation></ref>
<ref id="ref32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gashaw</surname> <given-names>F</given-names></name> <name><surname>Erko</surname> <given-names>B</given-names></name> <name><surname>Mekonnen</surname> <given-names>Y</given-names></name> <name><surname>Yenew</surname> <given-names>B</given-names></name> <name><surname>Amare</surname> <given-names>M</given-names></name> <name><surname>Gumi</surname> <given-names>B</given-names></name> <etal/></person-group>. <article-title>Phenotypic and genotypic drug sensitivity profiles of <italic>Mycobacterium tuberculosis</italic> infection and associated factors in northeastern Ethiopia</article-title>. <source>BMC Infect Dis</source>. (<year>2021</year>) <volume>21</volume>:<fpage>261</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-021-05961-8</pub-id>, PMID: <pub-id pub-id-type="pmid">33711936</pub-id></citation></ref>
<ref id="ref33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zewdie</surname> <given-names>O</given-names></name> <name><surname>Mihret</surname> <given-names>A</given-names></name> <name><surname>Abebe</surname> <given-names>T</given-names></name> <name><surname>Kebede</surname> <given-names>A</given-names></name> <name><surname>Desta</surname> <given-names>K</given-names></name> <name><surname>Worku</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Genotyping and molecular detection of multidrug-resistant <italic>Mycobacterium tuberculosis</italic> among tuberculosis lymphadenitis cases in Addis Ababa, Ethiopia</article-title>. <source>New Microbes New Infect</source>. (<year>2018</year>) <volume>21</volume>:<fpage>36</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nmni.2017.10.009</pub-id>, PMID: <pub-id pub-id-type="pmid">29675262</pub-id></citation></ref>
<ref id="ref34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wasihun</surname> <given-names>AG</given-names></name> <name><surname>Hailu</surname> <given-names>GG</given-names></name> <name><surname>Dejene</surname> <given-names>TA</given-names></name></person-group>. <article-title>Prevalence of <italic>Mycobacterium tuberculosis</italic> (rifampicin-resistant MTB) and associated risk actors among pulmonary presumptive TB patients in eastern Amhara, Ethiopia: 2015&#x2013;2019</article-title>. <source>Infect Dis Ther</source>. (<year>2021</year>) <volume>10</volume>:<fpage>1299</fpage>&#x2013;<lpage>308</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40121-020-00368-5</pub-id>, PMID: <pub-id pub-id-type="pmid">33950463</pub-id></citation></ref>
<ref id="ref35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selfegna</surname> <given-names>S</given-names></name> <name><surname>Alelign</surname> <given-names>A</given-names></name></person-group>. <article-title>Detection of mycobacterium tuberculosis and rifampicin resistance using GeneXpert MTB/RIF assay at Enat hospital, Central Ethiopia</article-title>. <source>Tuberc Res Treat</source>. (<year>2022</year>) <volume>2022</volume>:<fpage>1</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2022/1250404</pub-id>, PMID: <pub-id pub-id-type="pmid">35087689</pub-id></citation></ref>
<ref id="ref36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulu</surname> <given-names>W</given-names></name> <name><surname>Abera</surname> <given-names>B</given-names></name> <name><surname>Yimer</surname> <given-names>M</given-names></name> <name><surname>Hailu</surname> <given-names>T</given-names></name> <name><surname>Ayele</surname> <given-names>H</given-names></name> <name><surname>Abate</surname> <given-names>D</given-names></name></person-group>. <article-title>Rifampicin-resistance pattern of mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos referral hospital, Ethiopia: a cross-sectional study</article-title>. <source>BMC Res Notes</source>. (<year>2017</year>) <volume>10</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s13104-016-2328-4</pub-id></citation></ref>
<ref id="ref37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sinshaw</surname> <given-names>W</given-names></name> <name><surname>Kebede</surname> <given-names>A</given-names></name> <name><surname>Bitew</surname> <given-names>A</given-names></name> <name><surname>Tesfaye</surname> <given-names>E</given-names></name> <name><surname>Tadesse</surname> <given-names>M</given-names></name> <name><surname>Mehamed</surname> <given-names>Z</given-names></name> <etal/></person-group>. <article-title>Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia</article-title>. <source>BMC Infect Dis</source>. (<year>2019</year>) <volume>19</volume>:<fpage>1</fpage>&#x2013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-019-4241-7</pub-id></citation></ref>
<ref id="ref38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arega</surname> <given-names>B</given-names></name> <name><surname>Menbere</surname> <given-names>F</given-names></name> <name><surname>Getachew</surname> <given-names>Y</given-names></name></person-group>. <article-title>Prevalence of rifampicin resistant <italic>Mycobacterium tuberculosis</italic> among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia</article-title>. <source>BMC Infect Dis</source>. (<year>2019</year>) <volume>19</volume>:<fpage>1</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-019-3943-1</pub-id></citation></ref>
<ref id="ref39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mekonnen</surname> <given-names>F</given-names></name> <name><surname>Tessema</surname> <given-names>B</given-names></name> <name><surname>Moges</surname> <given-names>F</given-names></name> <name><surname>Gelaw</surname> <given-names>A</given-names></name> <name><surname>Eshetie</surname> <given-names>S</given-names></name> <name><surname>Kumera</surname> <given-names>G</given-names></name></person-group>. <article-title>Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia</article-title>. <source>BMC Infect Dis</source>. (<year>2015</year>) <volume>15</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-015-1202-7</pub-id></citation></ref>
<ref id="ref40"><label>40.</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Dejene</surname> <given-names>TA</given-names></name> <name><surname>Hailu</surname> <given-names>GG</given-names></name></person-group>, <source>Wasihun AG: Prevalence of mycobacterium tuberculosis and rifampicin-resistant tuberculosis among tuberculosis presumptive adults in Northern Ethiopia, 2016-2019</source>. (<year>2021</year>).</citation></ref>
<ref id="ref41"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Araya</surname> <given-names>S</given-names></name> <name><surname>Negesso</surname> <given-names>AE</given-names></name> <name><surname>Tamir</surname> <given-names>Z</given-names></name></person-group>. <article-title>Rifampicin-resistant <italic>Mycobacterium tuberculosis</italic> among patients with presumptive tuberculosis in Addis Ababa, Ethiopia</article-title>. <source>Infect Drug Resist</source>. (<year>2020</year>) <volume>13</volume>:<fpage>3451</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S263023</pub-id>, PMID: <pub-id pub-id-type="pmid">33116664</pub-id></citation></ref>
<ref id="ref42"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gebretsadik</surname> <given-names>D</given-names></name> <name><surname>Ahmed</surname> <given-names>N</given-names></name> <name><surname>Kebede</surname> <given-names>E</given-names></name> <name><surname>Mohammed</surname> <given-names>M</given-names></name> <name><surname>Belete</surname> <given-names>MA</given-names></name></person-group>. <article-title>Prevalence of tuberculosis by automated GeneXpert rifampicin assay and associated risk factors among presumptive pulmonary tuberculosis patients at Ataye District hospital, north East Ethiopia</article-title>. <source>Infect Drug Resist</source>. (<year>2020</year>) <volume>13</volume>:<fpage>1507</fpage>&#x2013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S248059</pub-id>, PMID: <pub-id pub-id-type="pmid">32547120</pub-id></citation></ref>
<ref id="ref43"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gebrehiwet</surname> <given-names>GB</given-names></name> <name><surname>Kahsay</surname> <given-names>AG</given-names></name> <name><surname>Welekidan</surname> <given-names>LN</given-names></name> <name><surname>Hagos</surname> <given-names>AK</given-names></name> <name><surname>Abay</surname> <given-names>GK</given-names></name> <name><surname>Hagos</surname> <given-names>DG</given-names></name></person-group>. <article-title>Rifampicin resistant tuberculosis in presumptive pulmonary tuberculosis cases in Dubti hospital, Afar, Ethiopia</article-title>. <source>J Infect Dev Ctries</source>. (<year>2019</year>) <volume>13</volume>:<fpage>21</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.3855/jidc.10462</pub-id>, PMID: <pub-id pub-id-type="pmid">32032019</pub-id></citation></ref>
<ref id="ref44"><label>44.</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Kelecha</surname> <given-names>WT</given-names></name> <name><surname>Teklegiorgis</surname> <given-names>SG-S</given-names></name> <name><surname>Gemechu</surname> <given-names>MM</given-names></name></person-group>: <source>Rifampicin-resistance pattern of mycobacterium tuberculosis and associated risk factors among presumptive pulmonary and extra pulmonary tuberculosis patients at Madda Walabu University Goba referral hospital, Southeast Ethiopia</source>. (<year>2021</year>).</citation></ref>
<ref id="ref45"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derbie</surname> <given-names>A</given-names></name> <name><surname>Worku</surname> <given-names>S</given-names></name> <name><surname>Mekonnen</surname> <given-names>D</given-names></name> <name><surname>Mezgebu</surname> <given-names>Y</given-names></name> <name><surname>Teshager</surname> <given-names>A</given-names></name> <name><surname>Birhan</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Xpert MTB/RIF assay for the diagnosis of mycobacterium tuberculosis and its rifampicin resistance at Felege Hiwot and Debre Tabor hospitals, Northwest Ethiopia: a preliminary implementation research</article-title>. <source>Ethiop J Health Dev</source>. (<year>2016</year>) <volume>30</volume>:<fpage>60</fpage>&#x2013;<lpage>6</lpage>.</citation></ref>
<ref id="ref46"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaleta</surname> <given-names>KN</given-names></name> <name><surname>Gizachew</surname> <given-names>M</given-names></name> <name><surname>Gelaw</surname> <given-names>B</given-names></name> <name><surname>Tesfa</surname> <given-names>H</given-names></name> <name><surname>Getaneh</surname> <given-names>A</given-names></name> <name><surname>Biadgo</surname> <given-names>B</given-names></name></person-group>. <article-title>Rifampicin-resistant <italic>Mycobacterium tuberculosis</italic> among tuberculosis-presumptive cases at University of Gondar Hospital, Northwest Ethiopia</article-title>. <source>Infect Drug Resist</source>. (<year>2017</year>) <volume>10</volume>:<fpage>185</fpage>&#x2013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S135935</pub-id>, PMID: <pub-id pub-id-type="pmid">28652786</pub-id></citation></ref>
<ref id="ref47"><label>47.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demissie</surname> <given-names>TA</given-names></name> <name><surname>Belayneh</surname> <given-names>D</given-names></name></person-group>. <article-title>Magnitude of <italic>Mycobacterium tuberculosis</italic> infection and its resistance to rifampicin using Xpert-MTB/RIF assay among presumptive tuberculosis patients at Motta general hospital, Northwest Ethiopia</article-title>. <source>Infect Drug Resist</source>. (<year>2021</year>) <volume>14</volume>:<fpage>1335</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S300585</pub-id>, PMID: <pub-id pub-id-type="pmid">33854346</pub-id></citation></ref>
<ref id="ref48"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diriba</surname> <given-names>K</given-names></name> <name><surname>Awulachew</surname> <given-names>E</given-names></name> <name><surname>Churiso</surname> <given-names>G</given-names></name></person-group>. <article-title>The magnitude of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among tuberculosis suspected patients in Gedeo zone, southern Ethiopia</article-title>. <source>Infect Drug Resist</source>. (<year>2021</year>) <volume>14</volume>:<fpage>3961</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S327607</pub-id>, PMID: <pub-id pub-id-type="pmid">34594119</pub-id></citation></ref>
<ref id="ref49"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zewdie</surname> <given-names>O</given-names></name> <name><surname>Dabsu</surname> <given-names>R</given-names></name> <name><surname>Kifle</surname> <given-names>E</given-names></name> <name><surname>Befikadu</surname> <given-names>D</given-names></name></person-group>. <article-title>Rifampicin-resistant multidrug-resistant tuberculosis cases in selected hospitals in Western Oromia, Ethiopia: cross-sectional retrospective study</article-title>. <source>Infect Drug Resist</source>. (<year>2020</year>) <volume>13</volume>:<fpage>3699</fpage>&#x2013;<lpage>705</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S274589</pub-id>, PMID: <pub-id pub-id-type="pmid">33116690</pub-id></citation></ref>
<ref id="ref50"><label>50.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whalen</surname> <given-names>CC</given-names></name> <name><surname>Zalwango</surname> <given-names>S</given-names></name> <name><surname>Chiunda</surname> <given-names>A</given-names></name> <name><surname>Malone</surname> <given-names>L</given-names></name> <name><surname>Eisenach</surname> <given-names>K</given-names></name> <name><surname>Joloba</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Secondary attack rate of tuberculosis in urban households in Kampala, Uganda</article-title>. <source>PLoS One</source>. (<year>2011</year>) <volume>6</volume>:<fpage>e16137</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0016137</pub-id>, PMID: <pub-id pub-id-type="pmid">21339819</pub-id></citation></ref>
<ref id="ref51"><label>51.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Z&#x00FC;rcher</surname> <given-names>K</given-names></name> <name><surname>Reichmuth</surname> <given-names>ML</given-names></name> <name><surname>Ballif</surname> <given-names>M</given-names></name> <name><surname>Loiseau</surname> <given-names>C</given-names></name> <name><surname>Borrell</surname> <given-names>S</given-names></name> <name><surname>Reinhard</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Mortality from drug-resistant tuberculosis in high-burden countries comparing routine drug susceptibility testing with whole-genome sequencing: a multicentre cohort study</article-title>. <source>Lancet Microbe</source>. (<year>2021</year>) <volume>2</volume>:<fpage>e320</fpage>&#x2013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2666-5247(21)00044-6</pub-id>, PMID: <pub-id pub-id-type="pmid">35252901</pub-id></citation></ref>
<ref id="ref52"><label>52.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tembo</surname> <given-names>BP</given-names></name> <name><surname>Malangu</surname> <given-names>NG</given-names></name></person-group>. <article-title>Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana</article-title>. <source>BMC Infect Dis</source>. (<year>2019</year>) <volume>19</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-019-4375-7</pub-id></citation></ref>
<ref id="ref53"><label>53.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onyedum</surname> <given-names>CC</given-names></name> <name><surname>Alobu</surname> <given-names>I</given-names></name> <name><surname>Ukwaja</surname> <given-names>KN</given-names></name></person-group>. <article-title>Prevalence of drug-resistant tuberculosis in Nigeria: a systematic review and meta-analysis</article-title>. <source>PLoS One</source>. (<year>2017</year>) <volume>12</volume>:<fpage>e0180996</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0180996</pub-id>, PMID: <pub-id pub-id-type="pmid">28704459</pub-id></citation></ref>
<ref id="ref54"><label>54.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ejeh</surname> <given-names>FE</given-names></name> <name><surname>Undiandeye</surname> <given-names>A</given-names></name> <name><surname>Okon</surname> <given-names>K</given-names></name> <name><surname>Moshood</surname> <given-names>KH</given-names></name></person-group>. <article-title>Prevalence of rifampicin resistance tuberculosis among HIV/TB coinfected patients in Benue state, Nigeria</article-title>. <source>Pan Afr Med J</source>. (<year>2021</year>) <volume>38</volume>:<fpage>203</fpage>. doi: <pub-id pub-id-type="doi">10.11604/pamj.2021.38.203.19034</pub-id>, PMID: <pub-id pub-id-type="pmid">33995809</pub-id></citation></ref>
<ref id="ref55"><label>55.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>A</given-names></name> <name><surname>Prasad</surname> <given-names>R</given-names></name> <name><surname>Balasubramanian</surname> <given-names>V</given-names></name> <name><surname>Gupta</surname> <given-names>N</given-names></name></person-group>. <article-title>Drug-resistant tuberculosis and HIV infection: current perspectives</article-title>. <source>HIV/AIDS</source>. (<year>2020</year>) <volume>12</volume>:<fpage>9</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.2147/HIV.S193059</pub-id></citation></ref>
<ref id="ref56"><label>56.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname> <given-names>Y</given-names></name> <name><surname>Zhang</surname> <given-names>W</given-names></name> <name><surname>Qiao</surname> <given-names>R-J</given-names></name> <name><surname>Tang</surname> <given-names>J</given-names></name></person-group>. <article-title>Risk factors for multidrug-resistant tuberculosis: a worldwide systematic review and meta-analysis</article-title>. <source>PLoS One</source>. (<year>2022</year>) <volume>17</volume>:<fpage>e0270003</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0270003</pub-id>, PMID: <pub-id pub-id-type="pmid">35709161</pub-id></citation></ref>
<ref id="ref57"><label>57.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faustini</surname> <given-names>A</given-names></name> <name><surname>Hall</surname> <given-names>AJ</given-names></name> <name><surname>Perucci</surname> <given-names>CA</given-names></name></person-group>. <article-title>Risk factors for multi-drug resistant tuberculosis in Europe: a systematic review</article-title>. <source>Thorax</source>. (<year>2005</year>) <volume>61</volume>:<fpage>158</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1136/thx.2005.045963</pub-id></citation></ref>
<ref id="ref58"><label>58.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hajissa</surname> <given-names>K</given-names></name> <name><surname>Marzan</surname> <given-names>M</given-names></name> <name><surname>Idriss</surname> <given-names>MI</given-names></name> <name><surname>Islam</surname> <given-names>MA</given-names></name></person-group>. <article-title>Prevalence of drug-resistant tuberculosis in Sudan: a systematic review and meta-analysis</article-title>. <source>Antibiotics</source>. (<year>2021</year>) <volume>10</volume>:<fpage>932</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics10080932</pub-id>, PMID: <pub-id pub-id-type="pmid">34438982</pub-id></citation></ref>
</ref-list>
</back>
</article>